KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Free Cash Flow (2016 - 2025)

Exact Sciences (EXAS) has disclosed Free Cash Flow for 16 consecutive years, with $180.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 77.03% to $180.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $416.4 million through Dec 2025, up 151.57% year-over-year, with the annual reading at $416.4 million for FY2025, 151.57% up from the prior year.
  • Free Cash Flow for Q4 2025 was $180.1 million at Exact Sciences, down from $190.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was $193.6 million in Q4 2022, with the low at -$207.4 million in Q1 2022.
  • Average Free Cash Flow over 5 years is $13.8 million, with a median of $7.7 million recorded in 2021.
  • The sharpest move saw Free Cash Flow plummeted 888.69% in 2022, then soared 13727.24% in 2024.
  • Over 5 years, Free Cash Flow stood at -$84.0 million in 2021, then skyrocketed by 330.6% to $193.6 million in 2022, then decreased by 18.23% to $158.3 million in 2023, then plummeted by 35.74% to $101.7 million in 2024, then surged by 77.03% to $180.1 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $180.1 million, $190.0 million, and $46.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.